Results 311 to 320 of about 2,867,692 (324)
Some of the next articles are maybe not open access.
Gastroduodenal Safety of Cyclooxygenase-2 Inhibitors
Current Pharmaceutical Design, 2003Cyclooxygenase-1 (COX-1) derived eicosanoids promote gastroprotective mucosal defenses and induce platelet aggregation. By sparing COX-1, COX-2 specific inhibitors provide effective anti-inflammatory and analgesic activity while substantially reducing the risk of peptic ulcer disease and GI bleeding compared to dual COX inhibitors (traditional NSAIDs).
openaire +3 more sources
Cyclooxygenase inhibitors: Scope of their use and development in cancer chemotherapy
Medicinal research reviews (Print), 2011M. N. A. Khan, Yong-Sup Lee
semanticscholar +1 more source
Correction: Cyclooxygenase-2 Inhibitors
Annals of Pharmacotherapy, 1999Barbara Storyk Klostermeyer +1 more
openaire +2 more sources
Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.
New England Journal of Medicine, 2002A. McQuillan, J. Eikelboom
semanticscholar +1 more source
Journal of Pharmacology and Experimental Therapeutics, 2010
K. Mandery +10 more
semanticscholar +1 more source
K. Mandery +10 more
semanticscholar +1 more source
Cyclooxygenase inhibitors--current status and future prospects.
European journal of medicinal chemistry, 2001G. Dannhardt, W. Kiefer
semanticscholar +1 more source